Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

Sex: All

Ages: 18 Years – 60 Years

Phase: NA

Enrollment: 38

Sponsor: Danish Headache Center

Summary

To investigate whether administration of calcitonin gene-related peptide (CGRP) binding monoclonal antibodies eptinezumab prevents pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) induced migraine attacks in migraine without aura patients.

Eligibility Criteria

Inclusion Criteria:Healthy volunteers of both sexes.18-60 years.50-100 kg.Women of childbearing potential must use adequate contraceptionHistory of migraine without aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria.No migraine preventive treatment.Exclusion Criteria:A history of serious somatic disease> 50 years of age at migraine onset.History of any other primary headaches disorder (except ≤ 5 monthly days with tension- type headache).Daily intake of any medication except contraceptives

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05635604). StuddyBuddy aggregates publicly available trial information.